



(51) International Patent Classification:

A61K 9/20 (2006.01) A61P 35/00 (2006.01)
A61K 31/5377 (2006.01)

(21) International Application Number:

PCT/IB2023/000477

(22) International Filing Date:

09 August 2023 (09.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/370,989 10 August 2022 (10.08.2022) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **GRANER, Oliver**; Novartis Pharma AG,
Postfach, 4002 Basel (CH). **HARLACHER, Cornelius,**
Stephan; Novartis Pharma AG, Postfach, 4002 Basel (CH).
HOOTON, Jennifer, Claire; Novartis Pharma AG, Post-
fach, 4002 Basel (CH). **IYER, Raman**; Novartis Pharma-

ceuticals Corporation, One Health Plaza, East Hanover, NJ
07936 (US). **SETHURAMAN, Vijay**; 38889 Riverbank
Terrace, Fremont, CA 94536 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: AMORPHOUS SOLID DISPERSIONS COMPRISING NAPORAFENIB



(57) Abstract: The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition comprising N (3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, or a pharmaceutically acceptable salt thereof. The present invention also provides a process for preparing said pharmaceutical compositions for oral administration and methods of treatment with said pharmaceutical compositions.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*